Matrix Capital Management Company, LP Zentalis Pharmaceuticals, Inc. Transaction History
Matrix Capital Management Company, LP
- $2.09 Billion
- Q3 2024
A detailed history of Matrix Capital Management Company, LP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Matrix Capital Management Company, LP holds 13,959,973 shares of ZNTL stock, worth $43.7 Million. This represents 2.45% of its overall portfolio holdings.
Number of Shares
13,959,973
Previous 13,959,973
-0.0%
Holding current value
$43.7 Million
Previous $57.1 Million
10.27%
% of portfolio
2.45%
Previous 0.43%
Shares
5 transactions
Others Institutions Holding ZNTL
# of Institutions
141Shares Held
67.9MCall Options Held
48.5KPut Options Held
89.6K-
Eventide Asset Management, LLC Boston, MA8.55MShares$26.8 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$15.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$14.4 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$9.73 Million2.71% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.72MShares$8.51 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $178M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...